3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Conditions
Acquired Immunodeficiency Syndrome
2
Sarcoma, Kaposi
1
Opportunistic Infections
1
Inflammation
1
HIV Infections
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Interventions
Ritonavir
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
dolutegravir
1
Papillomavirus Vaccines
1
Nucleosides
1
Nevirapine
1
Lopinavir
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
1
Emtricitabine
1
Darunavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Acquired Immunodeficiency Syndrome
×
Ritonavir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn
NCT00444379
2014-08-20
ARKS
University of California, San Francisco
Phase 4
Completed
224 enrolled